PRGO - Perrigo Company plc

NYSE - NYSE Delayed Price. Currency in USD
59.48
-0.35 (-0.58%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close59.83
Open60.23
Bid59.37 x 800
Ask59.82 x 900
Day's Range59.42 - 60.48
52 Week Range40.68 - 60.48
Volume859,158
Avg. Volume1,126,472
Market Cap8.096B
Beta (5Y Monthly)1.47
PE Ratio (TTM)32.92
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.84 (1.40%)
Ex-Dividend DateNov 25, 2019
1y Target EstN/A
All
News
Press Releases
  • Perrigo To Provide Self-Care Transformation Update At J.P. Morgan Healthcare Conference; Announces Robust Preliminary Unaudited Fourth Quarter 2019 Net Sales
    PR Newswire

    Perrigo To Provide Self-Care Transformation Update At J.P. Morgan Healthcare Conference; Announces Robust Preliminary Unaudited Fourth Quarter 2019 Net Sales

    Perrigo Company plc (NYSE: PRGO) (TASE: PRGO) Chief Executive Officer and President Murray S. Kessler will highlight the progress of the Company's transformation into a consumer self-care company and discuss certain financial metrics for recently completed periods later today at the 38th Annual J.P. Morgan Healthcare Conference.

  • PR Newswire

    Bernstein Litowitz Achieves Significant Victory Certifying Claims Against Perrigo (NYSE; TASE: PRGO) for Shareholders in Both the United States and Israel

    Prominent securities litigation firm Bernstein Litowitz Berger & Grossmann LLP ("BLB&G;") announces a key victory in the securities class action against Perrigo Company plc ("Perrigo" or the "Company"), with the certification of three classes of investors by a New Jersey federal court.

  • Perrigo Advances Consumer Self-Care Growth Strategy with Ranir Subsidiary Acquisition of Steripod® Toothbrush Accessory Brand
    PR Newswire

    Perrigo Advances Consumer Self-Care Growth Strategy with Ranir Subsidiary Acquisition of Steripod® Toothbrush Accessory Brand

    Perrigo Company plc (NYSE; TASE: PRGO) announced today that its Ranir subsidiary has acquired the assets of Steripod®, a leading toothbrush accessory brand and innovator in the toothbrush protector market, from Bonfit America Inc. The deal includes the Steripod® portfolio of antibacterial toothbrush protectors, kids' products and tongue cleaners. Terms of the deal were not disclosed.

  • Perrigo to Present at Upcoming Investor Conferences
    PR Newswire

    Perrigo to Present at Upcoming Investor Conferences

    Perrigo Company plc (NYSE; TASE: PRGO), today announced that CEO and President, Murray S. Kessler will present at the ICR Conference at 9:30 AM EST on Monday, January 13, 2020 at the Grande Lakes Orlando Resort in Orlando, Florida.

  • Perrigo to Present at the Morgan Stanley Global Consumer & Retail Conference
    PR Newswire

    Perrigo to Present at the Morgan Stanley Global Consumer & Retail Conference

    DUBLIN, Nov. 13, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), today announced that CEO and President, Murray S. Kessler and CFO, Ray Silcock, will present at the Morgan Stanley Global Consumer & Retail Conference at 10:00 AM EST on Wednesday, December 4, 2019. Perrigo Company plc (NYSE; TASE: PRGO) is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.

  • Perrigo Company plc Reports Third Quarter 2019 Financial Results
    PR Newswire

    Perrigo Company plc Reports Third Quarter 2019 Financial Results

    Continues Successful Transformation to a Consumer Self-Care Company Raises 2019 Adjusted EPS Guidance DUBLIN , Nov. 6, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider ...

  • Perrigo Announces Quarterly Dividend
    PR Newswire

    Perrigo Announces Quarterly Dividend

    DUBLIN, Nov. 4, 2019 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-care Products™", today announced that its Board of Directors declared a quarterly dividend of $0.21 per share, payable on December 17, 2019 to shareholders of record on November 29, 2019. Perrigo Company plc (NYSE; TASE: PRGO) is dedicated to making lives better by bringing "Quality, Affordable Self-Care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed.

  • Perrigo Company plc Issues Voluntary Worldwide Recall of Ranitidine Due to Possible Presence of Impurity, N-nitrosodimethylamine (NDMA) Impurity in the product
    PR Newswire

    Perrigo Company plc Issues Voluntary Worldwide Recall of Ranitidine Due to Possible Presence of Impurity, N-nitrosodimethylamine (NDMA) Impurity in the product

    TASE: PRGO) announced today that it has initiated a voluntary, worldwide product recall to the retail customer level of ranitidine (all pack sizes). NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.

  • Perrigo Announces Third Quarter Calendar Year 2019 Earnings Date
    PR Newswire

    Perrigo Announces Third Quarter Calendar Year 2019 Earnings Date

    TASE: PRGO), today announced that it will release its third quarter calendar year 2019 financial results on Wednesday, November 6, 2019. The Company will host a conference call beginning at 8:00 a.m. (EDT).

  • Perrigo® Hosts 175 West Michigan Students for Manufacturing Week Celebration
    PR Newswire

    Perrigo® Hosts 175 West Michigan Students for Manufacturing Week Celebration

    Students from Seven Area High Schools Spent the Day at Perrigo's Allegan, Mich. Plants: Manager from Valued Customer, Walmart, Demonstrated Perrigo Products' Retail Journey ALLEGAN, Mich. , Oct. 3, 2019 ...

  • Perrigo Announces the Relaunch of the AB Rated Generic Version of Transderm Scop® 1.5 MG
    PR Newswire

    Perrigo Announces the Relaunch of the AB Rated Generic Version of Transderm Scop® 1.5 MG

    TASE: PRGO) today announced the relaunch of the AB rated generic equivalent of Transderm Scop® (scopolamine 1.5 mg). Annual market sales of Transderm Scop® and therapeutic equivalents for the 12 months ending August 2019 were approximately $147 million. TASE: PRGO) is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at http://www.perrigo.com.

  • Perrigo To Present At Upcoming Investor Conferences
    PR Newswire

    Perrigo To Present At Upcoming Investor Conferences

    TASE: PRGO), today announced that CEO and President, Murray S. Kessler and CFO, Ray Silcock, will host one-on-one meetings at the Barclay's Global Consumer Staples Conference on September 5, 2019 in Boston. TASE: PRGO) is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at http://www.perrigo.com. Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements.

  • Perrigo Announces Patent Litigation Settlement for the Generic Version of Nascobal® Nasal Spray
    PR Newswire

    Perrigo Announces Patent Litigation Settlement for the Generic Version of Nascobal® Nasal Spray

    Perrigo Executive Vice President and President Rx Pharmaceuticals Sharon Kochan stated, "This settlement is another example of our long-term commitment and investments in our extended topicals strategy. TASE: PRGO) is dedicated to making lives better by bringing "Quality, Affordable Self-care Products™" that consumers trust everywhere they are sold. The Company is a leading provider of over-the-counter health and wellness solutions that enhance individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. Visit Perrigo online at http://www.perrigo.com. Certain statements in this press release are "forward-looking statements." These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements.

  • Perrigo Company plc Reports Second Quarter 2019 Financial Results, Reaffirms Outlook, Progresses Consumer Transformation
    PR Newswire

    Perrigo Company plc Reports Second Quarter 2019 Financial Results, Reaffirms Outlook, Progresses Consumer Transformation

    DUBLIN , Aug. 8, 2019 /PRNewswire/ -- GAAP ("reported") net sales were $1.15 billion , reflecting a 3% decline versus the prior year period. Non-GAAP ("adjusted") net sales increased ...

  • PR Newswire

    Perrigo Announces Resignation Of Jeffrey C. Smith From Its Board Of Directors

    TASE: PRGO), a leading provider of "Quality Affordable Self-Care Products™", today announced that Jeffrey C. Smith, Managing Member, Chief Executive Officer, and Chief Investment Officer of Starboard Value LP, who has been a director since 2017, has resigned from Perrigo's Board of Directors effective August 7, 2019. "It is with mixed emotions that I leave the Board of Directors of Perrigo. "We are fortunate to have recruited a world-class leader in Murray Kessler who has quickly assembled an outstanding management team and repositioned Perrigo as a leading self-care company with numerous opportunities for growth and improved efficiency.

  • Perrigo Announces Second Quarter Calendar Year 2019 Earnings Date
    PR Newswire

    Perrigo Announces Second Quarter Calendar Year 2019 Earnings Date

    TASE: PRGO), today announced that it will release its second quarter calendar year 2019 financial results on Thursday, August 8, 2019. The Company will host a conference call beginning at 8 a.m. (EDT).

  • Perrigo Completes Divestiture of Animal Health Business for $185 Million
    PR Newswire

    Perrigo Completes Divestiture of Animal Health Business for $185 Million

    TASE: PRGO) today announced that it has completed the previously announced divestiture of its Animal Health business to PetIQ (PETQ) for $185 million. Perrigo CEO and President Murray S. Kessler stated, "Completing the divestiture of the Animal Health business is an important step in the transformation of Perrigo into a consumer-focused self-care company.

  • GlobeNewswire

    PetIQ, Inc. Completes Acquisition of Perrigo Animal Health

    EAGLE, Idaho, July 08, 2019 -- PetIQ, Inc. (“PetIQ” or the “Company”) (Nasdaq: PETQ), a leading pet medication and wellness company, today announced effective today, it has.

  • Perrigo Announces FDA Final Approval and Launch Of The AB-rated Generic Version Of Metrogel-Vaginal® Gel
    PR Newswire

    Perrigo Announces FDA Final Approval and Launch Of The AB-rated Generic Version Of Metrogel-Vaginal® Gel

    TASE: PRGO) today announced its product development partner received final approval from the U.S. Food and Drug Administration for its AB-rated Abbreviated New Drug Application ("ANDA") referencing Metrogel-Vaginal® (metronidazole vaginal gel 0.75%).  Perrigo will acquire full ownership of the ANDA under a pre-existing arrangement with its partner within 30 days and anticipates launching this product immediately thereafter. The product is manufactured by Perrigo and was developed through its partnership with Capstone Development Solutions, a company of Water Street Healthcare Partners, a strategic investor focused exclusively on the health care industry. Perrigo Executive Vice President and President Rx Pharmaceuticals, Sharon Kochan stated, "This launch exemplifies Perrigo's commitment to developing and launching products within the extended topicals category.

  • PR Newswire

    Perrigo Completes Acquisition Of Ranir, Raises Guidance

    - Advances transformation to a consumer-focused, self-care company - Raises 2019 non-GAAP ("adjusted") diluted EPS guidance to between $3.75 - $4.05 (1), which includes accretion of $0.10 from ...

  • GlobeNewswire

    Sol-Gel Technologies Announces Seventh Agreement for Generic Product Candidates with Perrigo

    Consistent with Sol-Gel’s prior agreements with Perrigo, Perrigo will seek regulatory approval with the U.S. Food and Drug Administration (“FDA”) for these generic product candidates. If approved by the FDA, Perrigo has agreed to commercialize the generic product candidates in the United States.

  • PR Newswire

    INVESTOR ALERT: Monteverde & Associates PC Launches Legal Inquiry Regarding the Acquisition

    NEW YORK , May 22, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...

  • Perrigo Announces FDA Final Approval For AB Rated Generic Version Of Voltaren® Gel 1%
    PR Newswire

    Perrigo Announces FDA Final Approval For AB Rated Generic Version Of Voltaren® Gel 1%

    TASE: PRGO) today announced its partner received final approval from the U.S. Food and Drug Administration for its AB rated Abbreviated New Drug Application (ANDA) referencing Voltaren® Gel, 1% (diclofenac sodium topical gel, 1%). Perrigo will acquire full ownership of the ANDA under a pre-existing arrangement with its partner within 30 days. Perrigo will manufacture diclofenac sodium topical gel 1% in its plant in Israel.

  • Perrigo Unveils Self-Care Transformation Plan, 2019 Guidance And Long-Term Growth Targets At Investor Day
    PR Newswire

    Perrigo Unveils Self-Care Transformation Plan, 2019 Guidance And Long-Term Growth Targets At Investor Day

    Chief Executive Officer and President Murray S. Kessler, along with several key members of his leadership team, will share the Company's strategic plan, vision, and financial objectives while introducing their priorities for transforming Perrigo from a healthcare company to a consumer self-care company. Kessler commented, "We have begun the process of transformation to recapture what we call 'The Perrigo Advantage'. The team has been hard at work during my first six months as CEO, analyzing our challenges and most importantly, building actionable plans to reinvent the company.